Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin H Durham

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
The Journal of Clinical Investigation|October 8, 2020
Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesisBo Liu, Zhaoqi Liu, Sisi Chen, et al.
British Journal of Haematology|July 3, 2023
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasmsAnne S Reiner, Benjamin H Durham, Mariko Yabe, et al.
Nature|August 31, 2017
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative diseaseElvira Mass, Christian E Jacome-Galarza, Thomas Blank, et al.
Leukemia|November 17, 2021
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axisRan Weissman, Eli L Diamond, Julien Haroche, et al.
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
Cancer Discovery|May 10, 2019
A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1Evangelia Loizou, Ana Banito, Geulah Livshits, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
Blood|March 31, 2026
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic NeoplasmsGaurav Goyal, Oussama Abla, John K C Chan, et al.
Leukemia|November 8, 2024
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasmsMali Salmon-Divon, Refael Meyuchas, Ofer Shpilberg, et al.
Oncogene|September 2, 2018
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemiaAlok Swaroop, Jon A Oyer, Christine M Will, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Investigation|October 8, 2020
Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesisBo Liu, Zhaoqi Liu, Sisi Chen, et al.
British Journal of Haematology|July 3, 2023
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasmsAnne S Reiner, Benjamin H Durham, Mariko Yabe, et al.
Nature|August 31, 2017
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative diseaseElvira Mass, Christian E Jacome-Galarza, Thomas Blank, et al.
Leukemia|November 17, 2021
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axisRan Weissman, Eli L Diamond, Julien Haroche, et al.
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
Cancer Discovery|May 10, 2019
A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1Evangelia Loizou, Ana Banito, Geulah Livshits, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
Blood|March 31, 2026
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic NeoplasmsGaurav Goyal, Oussama Abla, John K C Chan, et al.
Leukemia|November 8, 2024
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasmsMali Salmon-Divon, Refael Meyuchas, Ofer Shpilberg, et al.
Oncogene|September 2, 2018
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemiaAlok Swaroop, Jon A Oyer, Christine M Will, et al.
Pageof 7